1. "Solid Tumor Oncology Division"
Formats
  1. Journal Article (10831)
  2. Meeting Abstract (9435)
  3. Review (542)
  4. Book Section (410)
  5. Editorial (324)
  6. Guidelines (154)
  7. Correspondence (115)
  8. Conference Paper (106)
  9. Research Letter (60)
  10. Miscellaneous (53)
  11. Book Whole (27)
Groups
  1. Solid Tumor Oncology Division (22057)
  2. Department of Medicine (22035)
  3. GSK Faculty (5880)
  4. Genitourinary Oncology Service (5608)
  5. Survivorship Research (5184)
  6. Gastrointestinal Oncology Service (4640)

More Groups

People
  1. Robert Motzer (1243)
  2. Howard Scher (1130)
  3. Clifford Hudis (905)
  4. Jedd Wolchok (905)
  5. Mark Kris (869)
  6. Leonard Saltz (790)

More People

Years
  1. 2025 (445)
  2. 2024 (1382)
  3. 2023 (1380)
  4. 2022 (1573)
  5. 2021 (1517)
  6. 2020 (1535)

More Years

Publications
  1. Journal of Clinical Oncology (5227)
  2. Annals of Oncology (1294)
  3. Cancer Research (1012)
  4. Clinical Cancer Research (768)
  5. Journal of Thoracic Oncology (530)
  6. Gynecologic Oncology (441)

More Publications

Publishers
  1. American Society of Clinical Oncology (5507)
  2. Elsevier Inc. (2651)
  3. American Association for Cancer Research (2316)
  4. Oxford University Press (1810)
  5. Nature Publishing Group (1026)
  6. Springer (975)

More Publishers

Results (22057)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Phase 1b/2 trial of ribociclib plus binimetinib in metastatic NRAS-mutant melanoma: Safety, efficacy, and recommended phase 2 dose (RP2D)
    Meeting Abstract

    Schuler, M. H.; Ascierto, P. A.; De Vos, F. Y. F. L.; Postow, M. A.; Van Herpen, C. M. L.; Carlin, M. S.; Sosman, J. A.; Berking, C.; Long, G. V.; Weise, A.; more...
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save
  • Clinical results with combination of anti-CD27 agonist antibody, varlilumab, with anti-PD1 antibody nivolumab in advanced cancer patients
    Meeting Abstract

    Sanborn, R. E.; Pishvaian, M. J.; Kluger, H. M.; Callahan, M. K.; Weise, A. M.; Lutzky, J.; Yellin, M. J.; Rawls, T.; Vitale, L.; Halim, A.; more...
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save
  • Baseline CTC subtype to predict outcomes on mCRPC patients (pts) receiving enzalutamide (E) compared to abiraterone (A)
    Meeting Abstract

    Scher, H. I.; Jendrisak, A.; Schreiber, N. A.; McLaughlin, B.; Graf, R. P.; Rodriguez, A.; Fleisher, M.; Lee, J.; Kelvin, J.; Wang, Y.; more...
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save
  • Combination of dabrafenib (DAB)
    Meeting Abstract

    Sherman, E. J.; Ho, A. L.; Baxi, S. S.; Dunn, L.; Korte, S. H.; Haque, S.; Ghossein, R. A.; Chen, H. X.; Pfister, D. G.
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save
  • Clinical and immunologic variables associated with outcomes following combination ipilimumab and nivolumab immunotherapy in melanoma
    Meeting Abstract

    Rosner, S.; Kwong, E.; Panageas, K.; Postow, M. A.
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save
  • Clinical versus radiographic progression and overall survival for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) from COU-AA-302
    Meeting Abstract

    Ryan, C. J.; Kheoh, T.; Scher, H. I.; De Porre, P.; Yu, M. K.; Morris, M. J.
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save
  • Evolution in multimodality management of locally advanced rectal cancer
    Meeting Abstract

    Roxburgh, C. S. D.; Strombom, P.; Lynn, P. B.; Cercek, A.; Saltz, L.; Gollub, M. J.; Crane, C. H.; Wu, A. J. C.; Shia, J.; Vakiani, E.; more...
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save
  • Use of phenotypic profiling to determine sensitivity of gemcitabine with nab-paclitaxel for front-line treatment of pancreatic cancer
    Meeting Abstract

    Ricigliano, M.; Cooper, B.; Bartlett, A.; Yu, K. H.
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save
  • Evaluation of a cell viability assay based on cultures of CTICs to identify treatment options in third-line pancreatic cancer
    Meeting Abstract

    Ricigliano, M.; Isacoff, W. H.; Ocean, A. J.; Cooper, B.; Welkie, M.; Bartlett, A.; Yu, K. H.
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save
  • Sunitinib in patients with metastatic renal cell carcinoma: Clinical outcome according to IMDC risk group
    Meeting Abstract

    Rini, B. I.; Hutson, T. E.; Figlin, R. A.; Lechuga, M.; Valota, O.; Serfass, L.; Casey, M.; Motzer, R. J.
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save